Dublin, July 20, 2017 (GLOBE NEWSWIRE) -- The "Axial spondyloarthritis (axSpA) Market and Forecast Analyst to 2024" report has been added to Research and Markets' offering.

Axial spondyloarthritis (axSpA) is a chronic, systemic, inflammatory rheumatic disease that predominantly affects the spine and sacroiliac (SI) joints, leading to chronic back pain. The chronic inflammation can eventually result in new bone formation in the SI joints and spine, causing permanent impairment in spinal mobility.

Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) are the two sub-diseases that comprise axSpA, the former of which is defined by radiographic evidence of inflammatory damage to the SI joints (radiographic sacroiliitis), whereas the latter is defined by findings of sacroiliitis on magnetic resonance imaging scans but without the detection of advanced sacroiliitis by conventional radiography.

The etiology of axSpA remains unclear, the condition is inheritable and genetics play a major role, with mutations in certain genes, including the human leukocyte antigen B27 gene, known to be associated with an increased risk of developing AS.

The initial signs and symptoms of the disease, including spinal pain and stiffness, are not specific to axSpA, therefore there is often a lag time between onset and diagnosis.

Studies suggest that axSpA is most prevalent in Caucasian populations and AS is typically more common in male adults, whereas nr-axSpA occurs more frequently in females.

Furthermore, axSpA is often associated with a series of extra-articular manifestations and co-morbidities, including uveitis, cardiovascular risk, and inflammatory bowel disease. As a result, direct medical spending on the diagnosis and treatment of these conditions intensifies axSpA's economic impact.

Key Topics Covered:

1. Forecast: Axial Spondyloarthritis

• Cimzia (certolizumab)
• Cosentyx (secukinumab)
• Enbrel (etanercept)
• Humira (adalimumab)
• Remicade (infliximab)
• Simponi (golimumab)
• Stelara (ustekinumab)
• Taltz (ixekizumab)

2. Treatment: Axial Spondyloarthritis

• Executive Summary
• Disease Definition and Diagnosis
• Current Treatment Options
• Prescribing Trends
• Compliance
• Treatment Challenges and Unmet Needs
• Impact of Pipeline Agents
• Impact of Biosimilars

3. Epidemiology: Axial Spondyloarthritis in the US, Japan, and 5EU

• Executive Summary
• Disease Background
• Sources and Methodology
• Forecast: Ankylosing Spondylitis
• Forecast: Non-Radiographic Axial Spondyloarthritis
• Forecast: Axial Spondyloarthritis
• Epidemiologist Insight
• Strengths and Limitations
• Appendix: Additional Sources

4. Marketed Drugs: Axial Spondyloarthritis

• Product profile: Cimzia
• Product profile: Cosentyx
• Product profile: Enbrel
• Product profile: Humira
• Product profile: Remicade
• Product profile: Simponi

5. Pipeline: Axial Spondyloarthritis

• Executive Summary
• Clinical Pipeline Overview
• Key Opinion Leader Research
• Product profile (late stage): Otezla
• Product profile (late stage): Stelara
• Product profile (late stage): Taltz

For more information about this report visit https://www.researchandmarkets.com/research/jvqf42/axial

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.